Lotus Pharmaceutical Co Ltd (1795) — Capital Reinvestment Ratio
Lotus Pharmaceutical Co Ltd (1795) has a Capital Reinvestment Ratio of 1.19x as of December 2025, meaning it reinvests 1% of its operating cash flow (NT$1.35 Billion) in capital expenditures (NT$1.60 Billion). Check Lotus Pharmaceutical Co Ltd (1795) tangible net worth to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Lotus Pharmaceutical Co Ltd Capital Reinvestment Ratio (2009–2025)
This chart tracks Lotus Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 13 annual periods. For the full cash flow conversion analysis, see Lotus Pharmaceutical Co Ltd operating cash flow efficiency.
Annual Capital Reinvestment Ratio for Lotus Pharmaceutical Co Ltd (2009–2025)
Year-by-year Capital Reinvestment Ratio for Lotus Pharmaceutical Co Ltd from 2009 to 2025. See 1795 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.58x | NT$7.48 Billion | NT$4.35 Billion | ▲ +144.4% |
| 2024 | 0.24x | NT$6.15 Billion | NT$1.47 Billion | ▼ -88.3% |
| 2023 | 2.03x | NT$1.61 Billion | NT$3.28 Billion | ▲ +1207.5% |
| 2022 | 0.16x | NT$3.72 Billion | NT$577.16 Million | ▼ -98.9% |
| 2021 | 13.50x | NT$119.66 Million | NT$1.62 Billion | ▲ +1217.2% |
| 2020 | 1.03x | NT$1.95 Billion | NT$2.00 Billion | ▼ -71.9% |
| 2019 | 3.64x | NT$302.81 Million | NT$1.10 Billion | ▲ +627.3% |
| 2018 | 0.50x | NT$796.98 Million | NT$399.07 Million | ▼ -67.6% |
| 2017 | 1.54x | NT$592.29 Million | NT$914.84 Million | ▲ +188.3% |
| 2016 | 0.54x | NT$1.23 Billion | NT$660.48 Million | ▲ +10.9% |
| 2015 | 0.48x | NT$1.08 Billion | NT$520.71 Million | ▼ -80.6% |
| 2010 | 2.49x | NT$59.19 Million | NT$147.57 Million | ▲ +786.5% |
| 2009 | 0.28x | NT$89.50 Million | NT$25.17 Million | — |